cells will choose a final pattern of gene regulation. At the interface between innate and adaptive response, dendritic cells (DC) patrol tissues, capture pathogens/antigens and, once activated through their PRRs, move to draining lymph nodes (LN) to prime T cells. Thus, in response to "pro-inflammatory" stimuli, DC reorganize their chemokine receptor array, their antigen uptake machinery, the expression of MHC and co-stimulatory molecules, and the secretion of directive cytokines and chemokines. This activation of antigen-presenting cells like DC is crucial to induction of adaptive immune responses.
There is a growing body ofliterature that suggests a central role of the PRRs for the development of autoimmune diseases (4) . Since binding of PAMPs and PRR is not univocal and large overlaps exist between ligands and receptors, the associations found are usually not as statistically significant as, e.g., the association ofHLA alleles with autoimmune disorders. Many of these polymorphisms affect the regulation of gene expression by DC leading to impairment of the acquisition of a pro-inflammatory secretory phenotype by pathogen-specific T cells.
TLRs represent the best-studied family of PRRs. TLRs have been conserved during evolution being first identified in Drosophila (Toll receptors) and then in mammals (Toll-Like-Receptors). Of all the mammalian TLRs, TlR2 has the capability of recognizing the widest range of PAMPs, and is important for the recognition of mycobacteria and gram-positive bacteria. TLR2 is a polymorphic molecule in human and mouse. In the following pages, we overview the recent literature that has unveiled the three-dimensional structure of TLR2, its ligands, signaling pathways and celltype distribution, and discuss its possible role as a modulator of autoimmunity.
TLR2 structure
All TLRs are type I transmembrane glycoproteins with a trimodular structure: l-extracellular domain, 2-transmembran domain and 3-intracellular domain. The extracellular region contains a highly variable number of leucine-rich repeat (LRR) domains that consists approximately of 20-30 amino acids with the conserved motif "LXXLXLXXN". The published structures of the extracellular domain of TLR I, 2, 3 and 4 demonstrate that these receptors are members of the "typical" subfamily of LRR superfamily proteins. TLR2 and -4 have an unusual architecture with irregular LRR sequences and lack the conserved asparagine required for maintaining the horseshoe-like structure. The LRR domain of TLR I, 2 and 4 can be divided into three subdomains: N-terminal, Central and C-terminal. The central domains have the more unusual structure with less sequence conservation. In the reported crystallography of the TLR I/TLR2/Pam3CSK4 complex, the extracellular domains of TLRI and 2 form an 'M' shaped structure with the two N-termini extending outwards in opposite directions and the C-termini with the central domain converging to the center. The lipid chain Pam3CSK4 is essential for the dimerization of TLR I and 2 since it bridges the two proteins lodging into the channel formed by ctermini and central LRR domain of the two receptors (5) . A schematic representation ofTLR2 structure is shown in Fig. I .
The intracellular region known as Toll IL-I receptor domain (TIR) bind adaptor molecules such as MYD88, TIRAP, TRIF and TRAM (6) following dimerization of the TLRs induced by the ligand. The crystal structure of TIR domain of the TLR I, -2 (7) and -10 (8) contains a central five-stranded parallel beta-sheet surrounded by a total of five helices on both sides. The analysis of TIR structure of TLR2 shows that the amino and carboxy termini are separated by a 14 Adistance, suggesting that TIR domain looks like a cassette. The BB loop region contains the highly conserved residues within the TIR domain.
TLR2 ligands
TLR2 recognize bacterial lipopetides and lipoproteins in association with TLR I or TLR6 (see Table I for a list ofTLR2 ligands).
A large number of lipropteins contain conserved tri-acylated cysteine, with the noteworthy exception of mycoplasma lipoprotein that contains di-acylated cystein at the N-termini. TLR2 binds one acylated tail of the cysteine. TLRI and TLR6 are essential for the recognition of tri-and di-acylated lipoprotein, respectively, (5) each binding two or more acyl groups.
TLR2, however, also binds more complex structures. Peptidoglycan, the major component of cell wall of gram-positive bacteria, enhances IL-6 production via TLR2 receptor (9) . Yet it activates DC and induces IL-12p70 secretion only in its multimeric form, while the monomeric form fails to do so (10) . Moreover, TLR2 represents the most important PRR in the innate response to mycobacteria. Several mycobacterial proteins have been shown to interact with TLR2 either directly or through enhancement of M tuberculosis-acylated glycolipids recognition byTLR2.
It has been shown that the large mycobacterial proteins PE_PGRS, which are found only in pathogenic mycobacteria and contain repetitive domains (11) induce DC activation through TLR2 (12) . These proteins localize in the mycobacteria outer membrane, where they are properly exposed to interact with host components (13) . Interestingly, the genome of M tuberculosis contains 60 PE_ PGRS genes and each gene is independently and differentially regulated during infection (14) . Lack of information on the three-dimensional structure of PE_PGRS proteins does not allow predicting a model for their binding to TLR2; yet, the observation that most ofthe genetic variability of M tuberculosis rests on PE_PGRS genes has prompted to speculate that PE_PGRS proteins may act as immunomodulatory element through interaction with TLR2. Finally, in addition to binding TLR4, LPS also binds TLR2, triggering DC activation.
In all of the above-mentioned cases, multimeric and/or repetitive large molecules are recognized by TLR2, making it likely that dimerization of the TLR2 [either heterodimers with other TLRs or homodimers (15) (16) (17) ] complex occurs also through interactions of binding sites distinct from the small acylated peptide-binding grove.
TLR2 ligands and autoimmunity
As mentioned above, TLR2 is the main receptor involved in recognition ofmycobacteria. The finding that amounts of inactivated or alive mycobacteria modulate the development of EAE (3) and diabetes (18) , represents paramount evidence that molecules activating innate immunity through TLR2 are also involved in the development of experimental autoimmunity.
The presence and amount of heat-killed M. tuberculosis in the adjuvant is critical for induction of EAE in susceptible strains. In respect to this observation, we have shown that presence but not amount of M. tuberculosis influences the number of myelin-specific, IFN-y secreting CD4+ cells in the model of relapsing remitting EAE developing in the SJL mouse upon immunization with PLP 139-15 I (19). On the contrary, in the same model, it is the amount of M. tuberculosis that modulates the number of myelin-specific, IFN-y secreting CD8+ cells that precede CD4+ cells into the CNS before the onset of EAE (3). It is still not clarified whether the two phenomena (recruitment of CD4 and polarization and CD8 cells, respectively) are regulated through engagement of the same PRR or rather through distinct PRRs.
The development of diabetes in NOD mice is particularly susceptible to modulation by bacterial products. Thus, it has been shown that early administration of CFA results in protection from diabetes development, unexpectedly accompanied by priming of Th 17 cells (18) .
Several recent papers have shown that another potential provider of TLR2 ligands, namely the enteric bacterial flora, modulates induction and protection from diabetes development (20) ; in addition, filamentous bacteria residing in the gut are essential in the regulation of susceptibility to development of arthritis and EAE (21) (22) ). This hypothesis is stongly supported by the obsevation that PSA from gut microbiota (in particular, B fragilis) acts through TLR2 to convert CD4+ T cells into FoxP3+ regulatory cells (23) .
TLR2 signaling
Toll-like receptor 2 (TLR2), like the entire family of mammalian TLRs, is a trans-membrane protein.
The signaling pathway through which TLR2 induces activation of cells of the innate immune responses is common to all TLRs and has been studied and described by several researchers in recent years (24) .
Following ligand binding, the TLRs dimerize, undergoing the conformational change requested for recruitment of downstream signaling molecules at the highly conserved cytoplasmic region known as TIR (Toll/ll-IR) domain. Downstream signaling molecules include MyD88, lRAKs, TAKI, TABI, TAB2 and TRF6 adaptor molecules, some of which are characterized by kinase activity. MyD88 was discovered as a gene product rapidly induced during IL-6-driven differentiation of M I myeloleukaemic cells into macrophages. Recruitment of MyD88 is carried out by its N-terminal death domain (DO), which associates to the death domain ofTIR through DO-DO interactions. Recruitment is followed by the engagement of members of the IRAK family of serine-threonin kinases.
Phosphorylated lRAK-1 is responsible for recruitment at the receptor complex and activation ofTRAF6, a member of the Tumor Necrosis Factor receptor (TNFR)-associated factor (TRAF) family of adaptor proteins that regulates cytokine production. Signaling proceeds through the IRAK-I/TRAF6 complex dissociation from the receptor, followed by its association with TAK-I (TGF-b-activated kinase I) and two TAK-I binding proteins, TAB I and TAB2.
The complex constituted by TRAF6, TAKI and TAB I moves in the cytoplasm, where it forms a larger complex with two other molecules, the E2 ligases Ubcl3 and UevlA proteins. Ubc13 and Uev l A catalyze the activation of TRAF6 which in turn activates TAKI, an ubiquitin-dependent kinase that eventually phosphorylates the IKK complex, consisting of IKKa, IKKband NEMO/IKKg, and MAP kinases, such as JNK. The final outcome of this signaling cascade is the activation of two transcription factors NF-kB and AP-l. NF-kB and AP I finally orchestrate the inflammatory response, consisting in the production of several inflammatory cytokines and other molecules involved in the adaptive immunity.
Therefore, it appears that TLR2 signaling, likewise signaling of the other cell membrane TLRs, leads to a common final result, i.e. the activation of the inflammatory response in a MyD88-dependent fashion. Accordingly, MyD88 kO mice do not show any production of inflammatory cytokines. In contrast to TLR3 and TLR4, TLR2 does not use a MyD88-independent pathway. MyD88-dependent events through TLR2 have been shown to be affected also by the deficiency of TIRAP, another TIR domain-containing adaptor protein that associates with the TIR domain ofTLR2 together with MyD88, resulting in PGN-induced NF-kB activation.
The existence of an additional NF-kB transactivation pathway involving TLR2 phosphorylation has been described, and several recent studies have focused the attention on the role of a TLR2-signaling pathway involving MyD88-PI3K-Racl-Akt. This pathway enhances ERK1I2, p38 MAPK and JNK 1/2 phosphorylation, which in tum leads to activation of NF-kB and onset of the inflammatory response. Activation of this pathway in murine macrophages leads to enhancement of phagocytosis of Lysteria monocytogenes (25) . Martinez and coli. (26) demonstrated that the TLR2-MyD88-PI3K-ERK is one ofthe signalling pathways required for cell activation and function in response to viral infection in NK cells. In human synovial fibroblasts, peptidoglycan, the major component of the cell wall of Gram-positive bacteria, enhances IL-6 production via TLR2 receptor, focal adhesion kinase, Akt and AP-I dependent pathway (9) . Results published by Quigley et al. (27) demonstrated that engagement of TLR2 in CD8 T cells promotes proliferation and survival of these cells in a manner dependent on PI3K-Akt pathway of activation, thereby highlighting a critical role for TLR-2 MyD88 signaling and PI3K-AKT pathway activation in CD8 T cell clonal expansion and memory formation.
Signals through TLR2, Th polarization and autoimmunity
As discussed previously, alterations of TLRs and of their signaling pathways are involved in immune disorders, and some reports relate TLR signaling pathways to autoimmune diseases.
IRAK-4-and MyD88-dependent pathways have been shown to be essential for removal ofdeveloping autoreactive B cells in humans (28) . Most of the data available connecting TLRs to autoimmunity are related to MyD88 that has been shown to be necessary for the induction ofEAE (29) . These observations represent evidence of a possible role for TLRs in the development of human diseases like MS (30) . Accordingly, the innate immune system plays a relevant role in autoimmune de-myelination (30) . Moreover, microglia express all known TLRs. Studies on the role of TLR2 in CNS infection show that this receptor amplifies neuroinflammation by pathogen recognition and cytokine production and induce apoptosis in microglia cells (31) (32) (33) .
Also activated T cells express TLRs, and in particular TLR2. While heterogeneity of CD4 cell was reported early (34) , only recently the CD4 subpopulation CD25+ FoxP3+ of regulatory Tcells (Treg) has been described and shown to.play a relevant role in the control of autoimmunity. A reduction of their output from the thymus has been reported in mice deficient in TRAF6 (35) . On the other hand, TLR2 signaling promotes polarization ofT helper cells towards the pro-inflammatory Th 17 phenotype, thereby supporting EAE induction (36) , while reducing the suppressor activity of Tregs (37) (38) (39) .
TLR polymorph isms and autoimmunity
Finding association of polymorphisms of a molecule with susceptibility to or protection -from a disease is an indirect indicator of a role for the molecule in the pathogenesis of the disease. So far, data describing associations of polymorphisms of TLR2 with autoimmune disease are not available. Rather, most attention has been drawn to the role that other TLRs activated by the adjuvant play, and concentrated in particular on TLR3, TLR4 and TLR9 (29) , although studies to date have provided some conflicting evidence for association of autoimmune diseases with polymorphisms of TLR4 and TLR9 (40) .
It may be hypothesized that TLR2 in humans is poorly polymorphic, at least in terms of the single nucleotide polymorphisms that can be examined in the high-throughput studies needed to examine large populations. However, full exon resequencing indicated that polymorphisms of TLR2 exist (41) . It may well be that existing polymorphisms of TLR2 do not alter its function up to a statistical relevance. In any case, a failure to find association of TLR2 polymorphisms with diseases does not exclude that TLR2 plays a role in mediating the potential modulating effects of infectious pathogens in the development of autoimmunity.
CONCLUSION
TLR2 plays a fundamental role in the recognition of molecular patterns derived from bacteria. A large number of observations briefly reviewed here suggests that TLR2 ligands, TLR2 signaling machinery and TLR2-induced T cell polarization are all essential for the development of autoimmunity, at least in some experimental models. Further studies focusing on TLR2 and on its co-receptors TLR I and TLR6 in human and experimental autoimmune disease will be needed to establish the role that TLR2 engagement by bacteria-derived motives plays in the pathogenesis of self-reactive diseases.
A further support to the role of TLR2 in the development of autoimmune diseases comes from the following paper: Socorro et aI., "Role for MyD88, TLR2 and TLR9 but not TLRI, TLR4 or TLR6 in experimental autoimmune encephalomyelitis" J Immunol 2011; 187:791-804, published after acceptance of this editorial.
